TrialSignal
Clinical trial intelligence report
Human Neural Progenitor Cells Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 17, 2026
NCT ID
NCT02943850
Status
COMPLETED
Phase
PHASE1
Sponsor
Cedars-Sinai Medical Center
Executive brief
Investment-Ready Snapshot
The investigator is examining the safety of transplanting cells that have been engineered to produce a growth factor into the spinal cord of patients with Amyotrophic Lateral Sclerosis (ALS). The cells are called neural progenitor cells, which are a type of stem cell that can become several different types of cells in the nervous system. These cells have been derived to specifically become astrocytes, which is a type of neuronal cell. The growth factor is called glial cell line-derived neurotrophic factor, or GDNF. GDNF is a protein that promotes the survival of many types of neuronal cells. Therefore, the cells are called "CNS10-NPC-GDNF." The investigational treatment has been tested in animals, but it has not yet been tested in people. In this study, we want to learn if CNS10-NPC-GDNF cells are safe to transplant into the spinal cords of people.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02943850
Indication
Amyotrophic Lateral Sclerosis
Modality
cell therapy
Target
Stem cell (HPC) implantation, Stereotactic surgical device
Intervention
Stem cell (HPC) implantation, Stereotactic surgical device
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.